News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BeiGene Co.,Ltd In-Licenses Two Potential Cancer Drugs from Janssen Pharmaceutica N.V.



10/14/2011 11:34:53 AM

October 14, 2011 -- BeiGene, based in Beijing’s Zhongguancun Life Science Park, has acquired China rights to two clinical-stage compounds, both of them oncology drug candidates, from Janssen Pharmaceutica NV, a division of Johnson & Johnson. Founded last year, BeiGene has an ambitious two-pronged business plan that combines in-licensing of five clinical stage drug candidates with developing its own novel drugs. The two drug candidates, intetumumab and MTKi-327, are the first acquisitions the company has made. More details....

Stock Symbol: (NYSE: JNJ)


Read at ChinaBio Today

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES